Skip to Main Content

Paper Details

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
NPJ Breast Cancer
69
2016
C9741, HER2, PAM50, PAM50 gene signatures, ROR, anthracycline, breast cancer, estrogen, estrogen receptor, gene signatures, patients, taxane, tumor, tumor samples
Author NameAffiliation
Minetta C LiuMayo Clinic
Elaine R MardisThe Genome Institute, Washington University
Elaine R MardisThe Genome Institute, Washington University
Sherri R DaviesWashington University School of Medicine
Jacqueline SniderWashington University School of Medicine
Marc L CitronHofstra North Shore-LIJ School of Medicine
Larry NortonMemorial Sloan-Kettering Cancer Center
Larry NortonMemorial Sloan-Kettering Cancer Center
Eric P WinerDana Farber Cancer Institute, Harvard Medical School
Clifford A HudisMemorial Sloan-Kettering Cancer Center
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina
Matthew J EllisSiteman Cancer Center, Washington University School of Medicine
  • 1 - 13

Datasets

Release 1.2